Physician profile
Keith D Curtis
NPI 1912994146
$480.89
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $14.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $140.44 | 2019 | |
| Merck Sharp & Dohme LLC | $83.07 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $75.35 | 2019 | |
| Pfizer INC. | $46.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.38 | 2019 | |
| Sanofi Pasteur INC. | $33.03 | 2019 | |
| Intersect Ent, INC. | $22.19 | 2019 | |
| Smith+Nephew, INC. | $17.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.35 | 2019 | |
| Gilead Sciences, INC. | $12.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.